ANI Maintains Course With Rare Disease Push In 2025
The Company Also Forecasts Potential Low Double-Digit Growth In Generics
Pushing onwards with its turn to rare disease, ANI discussed its latest plans at this year’s J.P. Morgan Healthcare Conference, setting the scene for further launches in the coming year.
